U.K. mulls adopting a 2-dose model for HPV vaccination

The United Kingdom is considering switching to a two-dose regimen for human papillomavirus immunization. A two-dose schedule for Gardasil--which is sold in Europe by a Merck ($MRK)-Sanofi ($SNY) joint venture--cleared the first European regulatory hurdle last month. If the U.K. adopts the two-shot model, it may use the cash it saves to vaccinate boys against HPV. Article

Suggested Articles

A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck’s rVSV-ZEBOV vaccine.

The partnership aims to make the production of vaccines that use adenovirus as vectors more cost-effective and contamination-free.

GSK's Shingrix has nabbed a huge chunk of the U.S. shingles-shot market, just five months after it was approved by the FDA.